Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.40 |
| ▸ | CA2 | P00918 | 9/20 | 0.40 |
| ▸ | CA9 | Q16790 | 8/20 | 0.40 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA7 | P43166 | 3/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.40 |
| ▸ | CA3 | P07451 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA6 | P23280 | 2/20 | 0.40 |
| ▸ | CA5A | P35218 | 2/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28468879 | 1.00 | CA1 (0.40) | CA1CA2CA9LPAR3CA12 | |
| SCHEMBL28644993 | 1.00 | CA1 (0.40) | CA1CA2CA9LPAR3CA12 | |
| SCHEMBL10626082 | 1.00 | CA1 (0.40) | CA1CA2CA9LPAR3CA12 | |
| Bromide SCHEMBL5500591 | 0.98 | CA1 (0.39) | CA1CA2CA9LPAR3CA12 | |
| Bromide SCHEMBL18394656 | 0.98 | CA1 (0.39) | CA1CA2CA9LPAR3CA12 | |
| SCHEMBL9124098 | 0.90 | ADRB2 (0.43) | CA1CA2CA9SMPD1TSHR | |
| SCHEMBL27094088 | 0.88 | LPAR3 (0.46) | LPAR3LPAR1LPAR2MEN1KMT2A | |
| Bromide SCHEMBL29050094 | 0.85 | GBA1 (0.38) | LPAR3LPAR1LPAR2DNM1SMPD1 | |
| SCHEMBL8440337 | 0.80 | DNM1 (0.46) | CA1CA2CA9CA12CA7 | |
| SCHEMBL6928943 | 0.79 | CA1 (0.31) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297466-B2 | Engineered Cas9 nucleases | EDITAS MEDICINE, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-20240228988-A1 | COMPOSITIONS AND METHODS FOR EFFICIENT GENOME EDITING | PRIME MEDICINE, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240141382-A1 | GENE EDITING COMPONENTS, SYSTEMS, AND METHODS OF USE | RENAGADE THERAPEUTICS MANAGEMENT INC., | 2024-05-02 | — | — | US | disclosed |
| US-11963982-B2 | CRISPR/RNA-guided nuclease systems and methods | EDITAS MEDICINE, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| WO-2024008967-A1 | LIPID NANOPARTICLES COMPRISING AN IMIDAZOLIUM-BASED CATIONIC LIPID | POLYPLUS TRANSFECTION (FR) | 2024-01-11 | — | — | WO | disclosed |
| CN-115671045-B | Non-liver-targeting nucleic acid nano preparation and preparation method and application thereof | 华南理工大学 | 2023-04-07 | — | — | CN | disclosed |
| CN-115671045-A | Non-liver-targeting nucleic acid nano preparation and preparation method and application thereof | 华南理工大学 | 2023-02-03 | — | — | CN | disclosed |
| US-20220177861-A1 | ENGINEERED CAS9 NUCLEASES | EDITAS MEDICINE, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20200354429-A1 | POLYNUCLEOTIDES ENCODING RELAXIN | MODERNATX, INC. (US) | 2020-11-12 | — | — | US | disclosed |
| US-20200155606-A1 | CRISPR/RNA-GUIDED NUCLEASE SYSTEMS AND METHODS | EDITAS MEDICINE, INC. (US) | 2020-05-21 | — | — | US | disclosed |
| US-20160090593-A1 | Lipid Formulated Compositions And Methods For Inhibiting Expression Of Transthyretin (TTR) | ALNYLAM PHARMACEUTICALS, INC. | 2016-03-31 | — | — | US | disclosed |
| US-20160076029-A1 | siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis | ALNYLAM PHARMACEUTICALS, INC. | 2016-03-17 | — | — | US | disclosed |
| US-20150050295-A9 | NOVEL LIPIDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | AXOLABS GMBH (DE) | 2015-02-19 | — | — | US | disclosed |
| US-20140288154-A1 | Lipid Formulated Compositions and Methods for Inhibiting Expression of Eg5 And VEGF Genes | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140170175-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | AXOLABS GMBH (DE) | 2014-06-19 | — | — | US | disclosed |
| EP-2496238-A1 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN (TTR) | Alnylam Pharmaceuticals, Inc. (US) | 2012-09-12 | — | — | EP | disclosed |
| CN-102316869-A | The treatment method for cancer | AMC AMSTERDAM | 2012-01-11 | — | — | CN | disclosed |
| CN-102164904-A | 6-substituted isoflavonoid compounds and uses thereof | NOVOGEN RES PTY LTD | 2011-08-24 | — | — | CN | disclosed |
| WO-2011056883-A1 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN (TTR) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20100267806-A1 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES | ALNYLAM PHARMACEUTICALS, INC. | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354429-A1 | POLYNUCLEOTIDES ENCODING RELAXIN | RXFP1, RXFP2, RXFP4 | CA1 4846/4885CA2 3887/4885CA9 4500/4885 |
| US-20150050295-A9 | NOVEL LIPIDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | PHOSPHO1, NPC1L1, PLIN3 | CA1 4071/4885CA2 2494/4885CA9 3446/4885 |
| US-20140288154-A1 | Lipid Formulated Compositions and Methods for Inhibiting Expression of Eg5 And VEGF Genes | KIF5A, KIF5C, KIF11 | CA1 4616/4885CA2 3977/4885CA9 3278/4885 |
| US-20160076029-A1 | siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis | TTR, CRYAA, SARNP | CA1 4883/4885CA2 4815/4885CA9 4660/4885 |
| US-20140170175-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | PHOSPHO1, NPC1L1, PLIN3 | CA1 4071/4885CA2 2494/4885CA9 3446/4885 |
| US-20200155606-A1 | CRISPR/RNA-GUIDED NUCLEASE SYSTEMS AND METHODS | ZFR, ADAR, RNGTT | CA1 4766/4885CA2 4647/4885CA9 3957/4885 |
| US-11963982-B2 | CRISPR/RNA-guided nuclease systems and methods | ZFR, ADAR, RNGTT | CA1 4766/4885CA2 4647/4885CA9 3957/4885 |
| US-20100267806-A1 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES | KIF5A, KIF5C, KIF11 | CA1 4616/4885CA2 3977/4885CA9 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.